{'fraction_non_alphanumeric': 0.02197802197802198, 'fraction_numerical': 0.013986013986013986, 'mean_word_length': 5.549019607843137, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Investigating the Selectivity of Novel Chalcones for Human Cancer Cells Compared to Non‐Cancerous Human Cell Lines

We previously presented data on the anticancer activity of a small library of synthetic flavonoid derivatives against glioblastoma and breast cancer lines in addition to several other human cancer cell lines. This data suggested that the chalcone structural backbone afforded more potent anticancer activity compared to its flavanone counterpart. Using this data, we selected three lead compounds: RK6, RK7, and RK15, to screen for activity against non‐cancerous cells to test for selectivity. Here we present updated IC50 values of these three analogs against MCF7 breast adenocarcinoma cells in addition to the previously reported data on the A‐172 glioblastoma cell line. To determine the selectivity of these lead compounds, RK6, RK7, and RK15 were screened against two non‐cancerous human cell lines: normal human astrocytes (NHA) and normal human mammary epithelial cells (NHME).